Mirum Pharmaceuticals, Inc. (MIRM): Results of Operations and Financial Condition
Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mirm-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update – Q2 2026 net product sales of $176 million – 2026 net product sales guidance increased to $680 million to $700 millio
How this was made
The 30-second read
Why it matters
The 8-K combines a financial update (Q2 results and raised 2026 net product sales guidance) with regulatory and clinical-path updates (volixibat Breakthrough and Orphan designations, pre-NDA discussion, and a revised NDA target to H1 2027).
Market read
Traders can update models for 2026 revenue expectations and regulatory timing risk for volixibat, while monitoring expense trajectory and upcoming clinical readouts in 2026-2027.
What to watch
Operating expenses rose sharply in Q2 2026, and the volixibat enrollment and topline milestones extend into 2027, increasing execution and financing risk.
Background
Mirum is a rare-disease biopharma with commercial product LIVMARLI and a pipeline including volixibat (cholestatic pruritus due to PSC/PBC) and zilurgisertib (FOP).
Ticker impact
Mirum raised 2026 net product sales guidance to $680M-$700M and disclosed FDA Breakthrough and Orphan designations for volixibat in PSC.
Bias toward upside on any market reaction, with follow-through risk tied to the FDA’s Phase 3 recommendation and upcoming topline timing.
The filing is a primary disclosure (8-K) with specific financial guidance, FDA designations, and a concrete change in the NDA target window.
Market effects
Reinforces investor appetite for rare-disease hepatology assets where FDA designations can accelerate development and market expectations.
Primarily US biotech sentiment via Nasdaq-listed issuer and FDA regulatory signals.
Limited direct global read-through beyond rare-disease hepatology and FDA-style designation effects.
Counterpoint
The FDA’s recommendation for a Phase 3 study suggests additional time and cost, which can dilute near-term valuation despite designations and guidance lift.
Key entities
- companyMirum Pharmaceuticals, Inc.
Nasdaq-listed rare-disease biopharma reporting Q2 2026 results, raising 2026 guidance, and updating volixibat regulatory and clinical timelines.
- drug_programVolixibat
IBAT inhibitor in cholestatic pruritus due to PSC/PBC; received Breakthrough Therapy and Orphan Drug designations for PSC and is now targeted for potential NDA submission in H1 2027.
- approved_productLIVMARLI (maralixibat)
Approved for pediatric cholestatic liver diseases; Q2 2026 net product sales were $128.7M, up 46% YoY.
- drug_programZilurgisertib
FOP program with a PDUFA target action date of September 26, 2026 for the NDA.
